Table 3.
Injection-Site Reactions Reported with Subcutaneously Administered Risperidone*
| Adverse Effect | Placebo | RBP-7000 | ||
|---|---|---|---|---|
| (n=118, 8 Weeks) | 90-mg (n=115, 8 Weeks) | 120-mg (n=117, 8 Weeks) | 120-mg (n=500, 52 Weeks) | |
| n (%) | n (%) | n (%) | n (%) | |
| Injection-site erythema | 6 (5.1) | 7 (6.1) | 5 (4.3) | 4 (0.8) |
| Injection-site pain | 23 (19.5) | 18 (15.7) | 26 (22.2) | 64 (12.8) |
| Injection-site nodule | 6 (5.1) | 3 (2.6) | 4 (3.4) | 34 (6.8) |
| Pruritus | 9 (7.5) | 6 (5.2) | 5 (4.3) | NA |
| Injection-site induration | NA | NA | NA | 34 (6.8) |
Notes: *Data from the published data from clinical studies (NCT02203838 and NCT02109562). Data that was not collected during the study were identified as not applicable (NA).